

## Utilizing Real World Evidence: Focus on Multiple Myeloma in Older Adults – Tweetorial #1

### References

#### Tweet 4

Lee HC, Ailawadhi S, Gasparetto CJ, et al. Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect<sup>®</sup> MM Registry. *Blood Cancer J.* 2021;11(7):134. doi:10.1038/s41408-021-00524-1

SEER. Cancer Stat Facts: Myeloma. National Cancer Institute. Bethesda, MD. Accessed December 20, 2021. <https://seer.cancer.gov/statfacts/html/mulmy.html>

Zhou L, Yu Q, Wei G, et al. Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. *BMC Cancer.* 2021;21(1):606. doi:10.1186/s12885-021-08280-y

#### Tweet 5

Palumbo A, Brinchen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. *Blood.* 2015;125(13):2068-2074. doi:10.1182/blood-2014-12-615187

#### Tweet 7

Facon T, Dimopoulos MA, Meuleman N, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. *Leukemia.* 2020;34(1):224-233. doi:10.1038/s41375-019-0539-0

#### Tweet 8

Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis.* 1987;40(5):373-383. doi:10.1016/0021-9681(87)90171-8

Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol.* 1982;5(6):649-55.

#### Tweet 9

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>): Multiple Myeloma (v4.2022). Updated December 14, 2021. Accessed December 23, 2021. [https://www.nccn.org/professionals/physician\\_gls/pdf/myeloma.pdf](https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf)

#### Tweet 10

Kumar SK, Jacobus SJ, Cohen AD, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. *Lancet Oncol.* 2020;21(10):1317-1330. doi:10.1016/s1470-2045(20)30452-6

**Tweet 11**

Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. *Lancet*. 2017;389(10068):519-527. doi:10.1016/s0140-6736(16)31594-x

**Tweet 12**

Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2021;22(11):1582-1596. doi:10.1016/s1470-2045(21)00466-6

**Tweet 13**

Facon T, Venner CP, Bahlis NJ, et al. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. *Blood*. 2021;137(26):3616-3628. doi:10.1182/blood.2020008787

**Tweet 14**

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Multiple Myeloma (v4.2022). Updated December 14, 2021. Accessed December 23, 2021. [https://www.nccn.org/professionals/physician\\_gls/pdf/myeloma.pdf](https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf)

**Tweet 16**

Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. *N Engl J Med*. 2016;374(17):1621-1634. doi:10.1056/NEJMoa1516282

NINLARO® (ixazomib). Prescribing information. Takeda Pharmaceuticals. March 2021. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/208462s010lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208462s010lbl.pdf)

Richardson PG, Kumar SK, Masszi T, et al. Final overall survival analysis of the TOURMALINE-MM1 Phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. *J Clin Oncol*. 2021;39(22):2430-2442. doi:10.1200/JCO.21.00972

**Tweet 17**

Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. *N Engl J Med*. 2016;374(17):1621-1634. doi:10.1056/NEJMoa1516282

Richardson PG, Kumar SK, Masszi T, et al. Final overall survival analysis of the TOURMALINE-MM1 Phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. *J Clin Oncol*. 2021;39(22):2430-2442. doi:10.1200/JCO.21.00972

#### **Tweet 19**

Dimopoulos MA, Stewart AK, Masszi T, et al. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. *Br J Haematol*. 2017;177(3):404-413. doi:10.1111/bjh.14549

Stewart AK, Dimopoulos MA, Masszi T, et al. Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma. *J Clin Oncol*. 2016;34(32):3921-3930. doi:10.1200/JCO.2016.66.9648

Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. *N Engl J Med*. 2015;372(2):142-152. doi:10.1056/NEJMoa1411321

#### **Tweet 20**

Hungria V, Beksac M, Weisel KC, et al. Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial. *Br J Haematol*. 2021;193(3):561-569. doi:10.1111/bjh.17321

Mateos MV, Sonneveld P, Hungria V, et al. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR. *Clin Lymphoma Myeloma Leuk*. 2020;20(8):509-518. doi:10.1016/j.clml.2019.09.623

Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. *N Engl J Med*. 2016;375(8):754-766. doi:10.1056/NEJMoa1606038

#### **Tweet 21**

Gavriatopoulou M, Terpos E, Dimopoulos MA. The extended 4-year follow-up results of the ELOQUENT-2 trial. *Oncotarget*. 2019;10(2):82-83. doi:10.18632/oncotarget.26527

Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. *N Engl J Med*. 2015;373(7):621-631. doi:10.1056/NEJMoa1505654

#### **Tweet 22**

Bahlis NJ, Dimopoulos MA, White DJ, et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. *Leukemia*. 2020;34(7):1875-1884. doi:10.1038/s41375-020-0711-6

Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. *N Engl J Med*. 2016;375(14):1319-1331. doi:10.1056/NEJMoa1607751

Plesner T, Dimopoulos MA, Oriol A, et al. Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial. *Br J Haematol*. 2021;194(1):132-139. doi:10.1111/bjh.17435

## Glossary

AE, adverse event  
AIDS, acquired immunodeficiency syndrome  
ADL, Activities of Daily Living  
CCI, Charlson Comorbidity Index  
CI, confidence interval  
CRR, complete response rate  
d, dexamethasone  
D, daratumumab  
DRd, daratumumab/lenalidomide/dexamethasone  
DVd, daratumumab/bortezomib/dexamethasone  
ECOG, Eastern Cooperative Oncology Group  
EloRd, elotuzumab/lenalidomide/dexamethasone  
GHS, global health status  
HR, hazard ratio  
IADL, Instrumental Activities of Daily Living  
IMD, immunomodulatory drugs  
IMWG, International Myeloma Working Group  
I, ixazomib  
IRd, ixazomib/lenalidomide/dexamethasone  
K, carfilzomib  
KRd, carfilzomib/lenalidomide/dexamethasone  
LSMD, least squares mean difference  
MACE, major adverse cardiovascular event  
MM, multiple myeloma  
mOS, median overall survival  
mPFS, median progression-free survival  
NCCN, National Comprehensive Cancer Network  
NDMM, newly diagnosed multiple myeloma  
NR, not reported  
OS, overall survival  
ORR, overall response rate  
PFS, progression-free survival  
PI, proteasome inhibitor  
PS, performance status  
QOL, quality of life  
R, lenalidomide  
Rd, lenalidomide/dexamethasone  
RRMM, relapsed/refractory multiple myeloma  
V, bortezomib  
Vd, bortezomib/dexamethasone  
VRd, bortezomib/lenalidomide/dexamethasone